Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Cupid rebounds 6% after sharp fall as upgraded FY27 guidance boosts sentiment
Cupid shares rebounded nearly 6% after a sharp correction in the previous session, as investors turned positive following the company’s upgraded FY27 revenue guidance of Rs 660 crore. Strong Q1 momentum, a robust order book, expanding global opportunities, and growth across healthcare, personal care, and wellness businesses helped revive sentiment toward the stock.
Sumitomo Chemical among 4 stocks that closed crossing below VWAP
Four Nifty500 stocks, Zydus Wellness, Sumitomo Chemical India, Max Healthcare Institute, and Zensar Technologies, closed over 1.5% below their VWAP on July 6, indicating potential bearish momentum and increased selling pressure, according to technical scan data.
India's wellness industry poised for growth amid focus on preventive healthcare, rising income: EBG Group chief
India's wellness market, valued at over $150 billion, is set for growth fueled by rising health consciousness and disposable incomes. EBG Group is launching Carlton Wellness India, an integrated ecosystem blending traditional Indian healing with modern hospitality. This platform will offer diverse wellness experiences, from city centers to retreats, emphasizing preventive care and holistic wellbeing for everyday life.
Stocks to Watch today: HDFC Bank, Coal India, Tata Steel, Sobha, BoB, Nykaa
Stocks to watch today: HDFC Bank, Coal India, Tata Steel, Sobha Ltd, Bank of Baroda, Radico Khaitan, Senco Gold, Fortis Healthcare, IndusInd Bank, Dabur, among others, will be in focus today.
Cupid shares gain 2% as firm raises FY27 guidance, expects Q1 revenue to top Rs 150 crore
Cupid shares gained 2% as the company anticipates a record Q1 FY27 revenue exceeding Rs 150 crore. Buoyed by strong market visibility, Cupid has boosted its FY27 revenue forecast to over Rs 660 crore. This optimistic outlook is fueled by diversified business, expanding global opportunities in healthcare, and growth in its condom and lubricant portfolios. The company is also making strides in its IVD business, signaling robust future potential.
Fluence deal signals Honasa’s pivot towards health-beauty convergence
As beauty consumers increasingly demand science-backed and holistic solutions, Honasa is blurring the lines between cosmetics, wellness and healthcare, with nutraceuticals emerging as a new battleground for growth and differentiation.
Omaxe Ltd leads gainers in 'B' group
Bajaj Healthcare Ltd, Prakash Pipes Ltd, Gujarat Natural Resources Ltd and Krishival Foods Ltd Partly Paidup are among the other gainers in the BSE's 'B' group today, 29 June 2026.
Worst is behind us, markets could hit new highs in 6-12 months: Envision’s Nilesh Shah
Nilesh Shah, Founder of Envision Capital, remains positive on digital platforms, defence, aerospace and consumer discretionary sectors, citing long-term domestic growth drivers. Shah expects stronger earnings, policy reforms and foreign investor participation to support markets, while also identifying opportunities linked to GLP-1 drugs, nutrition products and healthcare themes.
Godavari Biorefineries shares rises 10% on Japanese patent for cancer treatment invention
Godavari Biorefineries said the patented invention relates to the use of 5-Hydroxy-1,4-Naphthalenedione in the treatment of cancer and strengthens its intellectual property portfolio in the healthcare and life sciences space.
Alembic Pharmaceuticals receives USFDA tentative approval for Larotrectinib Capsules
Alembic Pharmaceuticals has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Larotrectinib Capsules, 25 mg and 100 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Vitrakvi Capsules, 25 mg and 100 mg, of Bayer Healthcare Pharmaceuticals Inc. (Bayer).
Aegis Logistics Ltd leads gainers in 'A' group
Blue Jet Healthcare Ltd, Wockhardt Ltd, DOMS Industries Ltd and Apar Industries Ltd are among the other gainers in the BSE's 'A' group today, 11 June 2026.
Haleon to invest Rs 2,000 crore to set up first India plant
Haleon is investing Rs 2,000 crore to build its first manufacturing plant in Pithampur, India. This move sharpens its focus on India, a fast-growing consumer healthcare market. The plant will produce oral-health products, including Sensodyne. It aims to reach one billion more consumers by 2030, with 300 million in India. The facility will also cater to export markets.